Literature DB >> 29431636

Germline Mutations in the Mitochondrial 2-Oxoglutarate/Malate Carrier SLC25A11 Gene Confer a Predisposition to Metastatic Paragangliomas.

Alexandre Buffet1,2, Aurélie Morin1,2, Luis-Jaime Castro-Vega1,2, Florence Habarou2,3, Charlotte Lussey-Lepoutre1,2, Eric Letouzé2,4,5,6,7, Hervé Lefebvre8, Isabelle Guilhem9, Magalie Haissaguerre10, Isabelle Raingeard11, Mathilde Padilla-Girola1, Thi Tran1,2, Lucien Tchara3, Jérôme Bertherat2,12,13, Laurence Amar1,2,13,14, Chris Ottolenghi2,3, Nelly Burnichon1,2,15, Anne-Paule Gimenez-Roqueplo16,2,13,15, Judith Favier16,2.   

Abstract

Comprehensive genetic analyses have identified germline SDHB and FH gene mutations as predominant causes of metastatic paraganglioma and pheochromocytoma. However, some suspicious cases remain unexplained. In this study, we performed whole-exome sequencing of a paraganglioma exhibiting an SDHx-like molecular profile in the absence of SDHx or FH mutations and identified a germline mutation in the SLC25A11 gene, which encodes the mitochondrial 2-oxoglutarate/malate carrier. Germline SLC25A11 mutations were identified in six other patients, five of whom had metastatic disease. These mutations were associated with loss of heterozygosity, suggesting that SLC25A11 acts as a tumor-suppressor gene. Pseudohypoxic and hypermethylator phenotypes comparable with those described in SDHx- and FH-related tumors were observed both in tumors with mutated SLC25A11 and in Slc25a11Δ/Δ immortalized mouse chromaffin knockout cells generated by CRISPR-Cas9 technology. These data show that SLC25A11 is a novel paraganglioma susceptibility gene for which loss of function correlates with metastatic presentation.Significance: A gene encoding a mitochondrial carrier is implicated in a hereditary cancer predisposition syndrome, expanding the role of mitochondrial dysfunction in paraganglioma. Cancer Res; 78(8); 1914-22. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29431636     DOI: 10.1158/0008-5472.CAN-17-2463

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

Review 1.  Pheochromocytoma/Paraganglioma: Is This a Genetic Disorder?

Authors:  Lauren Fishbein
Journal:  Curr Cardiol Rep       Date:  2019-07-31       Impact factor: 2.931

2.  Recurrent Germline DLST Mutations in Individuals with Multiple Pheochromocytomas and Paragangliomas.

Authors:  Laura Remacha; David Pirman; Christopher E Mahoney; Javier Coloma; Bruna Calsina; Maria Currás-Freixes; Rocío Letón; Rafael Torres-Pérez; Susan Richter; Guillermo Pita; Belén Herráez; Giovanni Cianchetta; Emiliano Honrado; Lorena Maestre; Miguel Urioste; Javier Aller; Óscar García-Uriarte; María Ángeles Gálvez; Raúl M Luque; Marcos Lahera; Cristina Moreno-Rengel; Graeme Eisenhofer; Cristina Montero-Conde; Cristina Rodríguez-Antona; Óscar Llorca; Gromoslaw A Smolen; Mercedes Robledo; Alberto Cascón
Journal:  Am J Hum Genet       Date:  2019-03-28       Impact factor: 11.025

3.  Genotype-phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis.

Authors:  Joakim Crona; Angela Lamarca; Suman Ghosal; Staffan Welin; Britt Skogseid; Karel Pacak
Journal:  Endocr Relat Cancer       Date:  2019-05       Impact factor: 5.678

Review 4.  What Have We Learned from Molecular Biology of Paragangliomas and Pheochromocytomas?

Authors:  Thomas G Papathomas; Diederik P D Suurd; Alfred K Lam; Ronald R de Krijger; Karel Pacak; Arthur S Tischler; Menno R Vriens
Journal:  Endocr Pathol       Date:  2021-01-12       Impact factor: 3.943

5.  PRSS37 deficiency leads to impaired energy metabolism in testis and sperm revealed by DIA-based quantitative proteomic analysis.

Authors:  Wenfeng Xiong; Haoyang Ge; Chunling Shen; Chaojie Li; Xiaohong Zhang; Lingyun Tang; Yan Shen; Shunyuan Lu; Hongxin Zhang; Zhugang Wang
Journal:  Reprod Sci       Date:  2022-04-26       Impact factor: 3.060

6.  HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: Metastatic pheochromocytomas and paragangliomas: proceedings of the MEN2019 workshop.

Authors:  Patricia L M Dahia; Roderick Clifton-Bligh; Anne-Paule Gimenez-Roqueplo; Mercedes Robledo; Camilo Jimenez
Journal:  Endocr Relat Cancer       Date:  2020-08       Impact factor: 5.678

Review 7.  The systems of metastatic potential prediction in pheochromocytoma and paraganglioma.

Authors:  Yong Wang; Minghao Li; Hao Deng; Yingxian Pang; Longfei Liu; Xiao Guan
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

8.  Genetic stratification of inherited and sporadic phaeochromocytoma and paraganglioma: implications for precision medicine.

Authors:  Ruth Casey; Hartmut P H Neumann; Eamonn R Maher
Journal:  Hum Mol Genet       Date:  2020-10-20       Impact factor: 6.150

Review 9.  Pheochromocytoma/paraganglioma: recent updates in genetics, biochemistry, immunohistochemistry, metabolomics, imaging and therapeutic options.

Authors:  Karren Antonio; Ma Margarita Noreen Valdez; Leilani Mercado-Asis; David Taïeb; Karel Pacak
Journal:  Gland Surg       Date:  2020-02

Review 10.  Surgical approach to patients with pheochromocytoma.

Authors:  Dhaval Patel
Journal:  Gland Surg       Date:  2020-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.